NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Ayman Saad, Alison W. Loren, Javier Bolaños‐Meade, George Chen, Daniel R. Couriel, Antonio Di Stasi, Areej El‐Jawahri, Hany Elmariah, Sherif S. Farag, Krishna Gundabolu, Jonathan A. Gutman, Vincent T. Ho, Rasmus T. Hoeg, Mitchell E. Horwitz, Joe L. Hsu, Adetola A. Kassim, Mohamed Kharfan Dabaja, John Magenau, Thomas Martin, Marco Mielcarek, Jonathan Moreira, Ryotaro Nakamura, Yago Nieto, Cameron Ninos, Caspian Oliai, Seema M. Patel, Brion Randolph, Mark A. Schroeder, Dimitrios Tzachanis, Asya Varshavsky‐Yanovsky, Madhuri Vusirikala, Frankie Algieri, Lenora A. Pluchino
Abstract
The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease-a major complication of allogeneic HCT-to enable the patient and clinician to assess management options in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.